This is a summary of a human clinical trial that concluded in April 2024 concerning the efficacy of RiboCeine (d-ribose-l-cysteine) for raising glutathione in the body.
What You Need to Know
Study Title:
Effect of D-Ribose L-Cysteine (RiboseCysteine) on oxidative stress markers and glutathione levels in healthy individuals aged 38 – 60
Study Facts:
- Double-blind Placebo Controlled Study
- Study protocol approved by the University of Santa Catarina (UNISUL) Ethics Committee (Protocol #6.597.558) (2023)
- All participants were healthy individuals
- RiboCeine 250 mg (MaxOne) per day versus Placebo
- Each participant followed the protocol for 28 days; but each had a different start date.
- Study start: 2023-11-01
- Experiment end: 2024-03-27
- Report Delivery: April 2024
General Objectives:
Investigate the effect of RiboseCysteine on serum markers of oxidative stress, inflammation and subjective measures of health.
Objective Measures:
- Total Serum Glutathione Levels
- Oxidative Stress Markers
- Mitochondrial Function
- Serum Inflammatory and Anti-inflammatory Cytokines
Results Summary:
- Age 38-60 full group: 26.6% Increase in Serum Glutathione levels versus the Placebo group
- Age 35-50 sub-group: 16.5% Increase in Serum Glutathione levels
- Age 51-60 sub-group: 64.7% Increase in Serum Glutathione levels
- No Negative Side Effects
- Improved blood flow to the prefrontal cortex
- Improved heart variability measurements, including heart rate
- Decreased fat mass
- Serum markers of oxidative stress and inflammation showed improvements relative to the Placebo group
To see a Press Release from the independent firm that conducted the study go here: RiboCeine Clinical Trial Press Release